Search Results - "Levy, J. H."

Adult extracorporeal membrane oxygenation: an international survey of transfusion and anticoagulation techniques by Esper, S. A., Welsby, I. J., Subramaniam, K., John Wallisch, W., Levy, J. H., Waters, J. H., Triulzi, D. J., Hayanga, J. W. A., Schears, G. J.

“…Background and objectives Extracorporeal membrane oxygenation (ECMO) is a method of life support for either isolated cardiac failure or respiratory failure,…”
Get full text

Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model by Bolliger, D., Szlam, F., Molinaro, R.J., Rahe-Meyer, N., Levy, J.H., Tanaka, K.A.

“…Replacement of fibrinogen is presumably the key step in managing dilutional coagulopathy. We performed an in vitro study hypothesizing that there is a minimal…”
Get full text

Haemodilution-induced profibrinolytic state is mitigated by fresh-frozen plasma: implications for early haemostatic intervention in massive haemorrhage by Bolliger, D., Szlam, F., Levy, J.H., Molinaro, R.J., Tanaka, K.A.

“…Fibrinolysis contributes to coagulopathy after major trauma and surgery. We hypothesized that progressive haemodilution is responsible, at least in part, for…”
Get full text

Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis by Iba, T., Levy, J. H.

“…Summary The inflammatory response and the activation of coagulation are two important responses in a host's defense against infection. These mechanisms do not…”
Get full text

Derangement of the endothelial glycocalyx in sepsis by Iba, T., Levy, J. H.

“…Summary The vascular endothelial surface is coated by the glycocalyx, a ubiquitous gel‐like layer composed of a membrane‐binding domain that contains…”
Get full text

Perioperative management of the bleeding patient by Ghadimi, K, Levy, J.H., Welsby, I.J.

“…Perioperative bleeding remains a major complication during and after surgery, resulting in increased morbidity and mortality. The principal causes of…”
Get full text

When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH by Levy, J. H., Ageno, W., Chan, N. C., Crowther, M., Verhamme, P., Weitz, J. I.

Get full text

Cryoprecipitate therapy by Nascimento, B., Goodnough, L.T., Levy, J.H.

“…Cryoprecipitate, originally developed as a therapy for patients with antihaemophilic factor deficiency, or haemophilia A, has been in use for almost 50 yr…”
Get full text

Periprocedural antiplatelet therapy: recommendations for standardized reporting in patients on antiplatelet therapy: communication from the SSC of the ISTH by Spyropoulos, A. C., Albaladejo, P., Godier, A., Greinacher, A., Hron, G., Levy, J. H., Samama, C. M., Douketis, J. D.

Get full text

Prevention and treatment of coagulopathy in patients receiving massive transfusions by Levi, M., Fries, D., Gombotz, H., van der Linden, Ph, Nascimento, B., Callum, J. L., Bélisle, S., Rizoli, S., Hardy, J.-F., Johansson, P. I., Samama, C. M., Grottke, O., Rossaint, R., Henny, C. P., Goslings, J. C., Theusinger, O. M., Spahn, D. R., Ganter, M. T., Hess, J. R., Dutton, R. P., Scalea, T. M., Levy, J. H., Spinella, P. C., Panzer, S., Reesink, H. W.

Get full text

Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass by Avidan, M.S., Levy, J.H., van Aken, H., Feneck, R.O., Latimer, R.D., Ott, E., Martin, E., Birnbaum, D.E., Bonfiglio, L.J., Kajdasz, D.K., Despotis, G.J.

“…We sought to evaluate the efficacy of recombinant human antithrombin III for restoration of heparin responsiveness in heparin-resistant patients scheduled for…”
Get full text

Weal and flare responses to intradermal rocuronium and cisatracurium in humans by Levy, J.H., Gottge, M., Szlam, F., Zaffer, R., McCall, C.

“…Thirty volunteers underwent intradermal skin testing with increasing concentrations of rocuronium and cisatracurium to evaluate weal and flare responses, and…”
Get full text

Aprotinin is useful as a hemostatic agent in cardiopulmonary surgery: yes by LEVY, J. H.

Get full text

Differential diagnoses for sepsis‐induced disseminated intravascular coagulation: communication from the SSC of the ISTH by Iba, T., Levy, J. H., Wada, H., Thachil, J., Warkentin, T. E., Levi, M.

Get full text

Use of factor concentrates for the management of perioperative bleeding: guidance from the SSC of the ISTH by Godier, A., Greinacher, A., Faraoni, D., Levy, J. H., Samama, C. M.

Get full text

Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers by Levi, M., Moore, K. T., Castillejos, C. F., Kubitza, D., Berkowitz, S. D., Goldhaber, S. Z., Raghoebar, M., Patel, M. R., Weitz, J. I., Levy, J. H.

“…Summary Background Four‐factor prothrombin complex concentrates (PCCs), which contain factor II, FVII, FIX, and FX, have shown the potential to reverse the…”
Get full text

The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran by Simon, A., Domanovits, H., Ay, C., Sengoelge, G., Levy, J. H., Spiel, A. O.

“…Essentials Reversal of anticoagulant effects of dabigatran may occur despite application of idarucizumab. Monitoring of dabigatran level after antidote…”
Get full text

Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy by Rahe-Meyer, N., Levy, J.H., Mazer, C.D., Schramko, A., Klein, A.A., Brat, R., Okita, Y., Ueda, Y., Schmidt, D.S., Ranganath, R., Gill, R.

“…Single-dose human fibrinogen concentrate (FCH) might have haemostatic benefits in complex cardiovascular surgery. Patients undergoing elective aortic surgery…”
Get full text

Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers by Levy, J. H., Moore, K. T., Neal, M. D., Schneider, D., Marcsisin, V. S., Ariyawansa, J., Weitz, J. I.

“…Essentials Specific reversal agents for managing severe factor Xa inhibitor‐associated bleeding are lacking. We assessed 4‐factor‐prothrombin complex…”
Get full text

Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery by Carrier, M., Ménasché, P., Levy, J.H., Newman, M.F., Taylor, K.M., Haverich, A., Chen, J.C., Shernan, S.K., Van de Werf, F., van der Laan, M., Todaro, T.G., Adams, P.X., Verrier, E.D.

“…We sought to evaluate the effects of pexelizumab, a C5 complement inhibitor, on death and myocardial infarction in patients undergoing combined aortic valve…”
Get full text